Related Experiment Videos
Platelet GPIIb-IIIa blockers
E J Topol1, T V Byzova, E F Plow
1Joseph J Jacobs Center for Thrombosis and Vascular Biology, Department of Cardiology, Cleveland Clinic Foundation, Ohio 44195, USA. topole@cesmtp.ccf.org
Lancet (London, England)
|January 29, 1999
Summary
Glycoprotein IIb/IIIa (GPIIb-IIIa) blockers significantly reduce the risk of death or myocardial infarction in patients with acute coronary syndromes. These antiplatelet drugs offer an effective alternative to aspirin monotherapy.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Platelet aggregation is crucial in thrombotic events.
- The alpha(IIb)beta3 integrin receptor plays a key role in platelet aggregation.
- Current antiplatelet therapies, like aspirin, have limitations.
Purpose of the Study:
- To evaluate the efficacy and safety of Glycoprotein IIb/IIIa (GPIIb-IIIa) blockers.
- To compare GPIIb-IIIa blockers with placebo in clinical trials.
- To assess the role of GPIIb-IIIa blockers in managing cardiovascular events.
Main Methods:
- Analysis of 10 phase III randomized clinical trials.
- Inclusion of patients undergoing percutaneous coronary intervention or with acute coronary syndrome on aspirin.
- Evaluation of endpoints including death and non-fatal myocardial infarction.
Main Results:
- GPIIb-IIIa blockers demonstrated a significant risk reduction of approximately 21% for death or non-fatal myocardial infarction.
- The risk of bleeding was not a major concern when heparin dosage was carefully managed.
- Active drugs consistently favored over placebo across all trials.
Conclusions:
- GPIIb-IIIa blockers represent a significant advancement in antiplatelet therapy.
- These agents offer superior efficacy compared to aspirin monotherapy for platelet inhibition.
- GPIIb-IIIa blockers are effective in high-risk cardiovascular settings.